πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 92 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11395822

Methods for treating Huntington's disease

PTC THERAPEUTICS, INC. Β· Granted Tue Jul 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11382918

Methods for treating Huntington's Disease

PTC THERAPEUTICS, INC. Β· Granted Tue Jul 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11198682

Substituted pyrimidines as inhibitors for a Rho family of GTP-ases

The Regents of the University of California Β· Granted Tue Dec 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11155834

Sin Nombre virus full-length M segment-based DNA vaccines

The Government of the United States, as represented by the Secretary of the Army Β· Granted Tue Oct 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11110154

Methods and compositions for treating Huntington's Disease

Sangamo Therapeutics, Inc. Β· Granted Tue Sep 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11096946

Use of a PPAR-Ξ΄ agonist for reducing loss of muscle strength, muscle mass, or type I muscl

VTV THERAPEUTICS LLC Β· Granted Tue Aug 24 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 19 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11072794

Compositions and their uses directed to huntingtin

Ionis Pharmaceuticals, Inc. Β· Granted Tue Jul 27 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10881658

Methods for treating Huntington's disease

PTC THERAPEUTICS, INC. Β· Granted Tue Jan 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10882886

Adeno-associated virus polynucleotides, polypeptides and virions

THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (WASHINGTON DC) Β· Granted Tue Jan 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10874672

Methods for treating Huntington's disease

PTC THERAPEUTICS, INC. Β· Granted Tue Dec 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10857203

Methods and compositions for treating Huntington's disease

Sangamo Therapeutics, Inc. Β· Granted Tue Dec 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10837016

Modulation of huntingtin expression

Ionis Pharmaceuticals, Inc. Β· Granted Tue Nov 17 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10814007

Angiotensinogen (AGT) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10709728

Polynucleotide agents targeting angiotensinogen (AGT) and methods of use thereof

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Jul 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10689392

Anti-cancer compounds targeting ral GTPases and methods of using the same

The Regents of the University of Colorado, a Body Corporate Β· Granted Tue Jun 23 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10676480

Anti-cancer compounds targeting Ral GTPases and methods of using the same

The Regents of the University of Colorado, a Body Corporate Β· Granted Tue Jun 09 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10655129

Compositions and their uses directed to huntingtin

Ionis Pharmaceuticals, Inc. Β· Granted Tue May 19 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 14 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10619158

Modulation of huntingtin expression

Ionis Pharmaceuticals, Inc. Β· Granted Tue Apr 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10471123

Methods and compositions for treating Huntington's disease

Sangamo Therapeutics, Inc. Β· Granted Tue Nov 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10456406

Use of a PPAR-Ξ΄ agonist for reducing loss of muscle strength, muscle mass, or type I muscl

VTV THERAPEUTICS LLC Β· Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10443073

Sin Nombre virus full-length M segment-based DNA vaccines

The Government of the United States, as represented by the Secretary of the Army Β· Granted Tue Oct 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10400036

Compositions and methods for increasing muscle mass and muscle strength by specifically an

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10369201

Methods and compositions for treating Huntington's disease

Sangamo Therapeutics, Inc. Β· Granted Tue Aug 06 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10335365

Bladder cancer specific ligand peptides

The United States of America as represented by the Department of Veteran Affairs (Washington DC) Β· Granted Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted